Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
about
Discoidin Domain Receptors: Potential Actors and Targets in CancerTargeting Src family kinases in anti-cancer therapies: turning promise into triumphMutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Regulation of SRC family kinases in human cancersExtracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgeryTransforming growth factor β signaling overcomes dasatinib resistance in lung cancerSrc inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyPhase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancerTyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.An update on dual Src/Abl inhibitors.Phase II study of dasatinib in patients with advanced non-small-cell lung cancerDetection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomicsDisruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.Response to combined molecular targeting: defining the role of P-STAT3.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung CancerPhase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patientsA Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer.Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.Src-signaling interference impairs the dissemination of blood-borne tumor cellsCharacterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.Activation of abl family kinases in solid tumors.New targetable oncogenes in non-small-cell lung cancer.Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesNon-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaTargeting genomic alterations in squamous cell lung cancer.The current state of the art of quantitative phosphoproteomics and its applications to diabetes research
P2860
Q26751157-54DCAC86-C338-4F47-8EF7-F7D0BA997C54Q27025646-F89920AB-5AD3-463E-9B90-366D89C912ADQ27851720-2A789888-1674-4580-9B2C-D643DA861152Q28243770-75A8BC24-63E1-4CE8-BD8C-245651110B4DQ28250096-DBCD5F76-E863-417C-B5C4-E3D3ED193721Q28542671-E4532B9F-1B3B-49E4-8D14-5189296C1F04Q30278774-A0BCA9EB-A870-4625-9146-E1011CAB3BE7Q30424531-03A5A4A5-D97C-405D-BBD5-8DAEBB935FEFQ33770326-66F2EBEE-5D5B-408F-82DD-D8BCDEDB650BQ33828409-2B658D88-F1FC-4D3E-BF7C-82B6B08C2614Q33940893-F0F1275D-5790-4A79-A90D-DB260B0F44A9Q33992604-12160982-A0AA-445D-801E-88076890F6F3Q34099289-CD784A91-448C-443D-88FA-B77D0C87EDECQ34121339-F5BB8234-F112-4DA8-B137-BEA00E151251Q34270677-A1454800-230C-46C5-B7BA-529B78D40EDDQ34281221-7DB32D9F-43F6-42CF-A40F-5A2CE03EC342Q34301120-118863BB-3167-4F91-B495-16CE386CFA81Q34458274-E7540646-0D7A-4A87-BD2E-4843DF014C17Q34667764-8E68106B-7177-432E-A8E7-575951EE50F4Q34747847-FD9D4DFD-2D73-46F4-A0AE-A93CA2373359Q34754045-EC7C0A04-DE0D-4649-9C0E-28E19902EFE2Q35077627-BB2A066D-AE14-498C-AF3B-FCE22883CC57Q35146581-2C5FA7A6-308C-4267-B7CB-1E59230F0688Q35584482-60302912-FA7C-4F8F-A6C3-D5E2D6B5EAE6Q35587056-EAC804CD-D364-4E14-9D0F-1D0CEE0764C3Q35592279-5C615D89-6595-4717-A29D-90C5107D47C6Q35659675-83BF05C9-82C3-4751-A151-FFAE7F24D4CDQ35829847-E7FC5057-CC64-4C8C-A040-5D34A0D15ACBQ35999362-1E351684-EEE1-45EB-AF8D-8E3423F7D045Q36109785-78D6B673-4D63-4523-B502-ADB6BCEA37E8Q36140620-18530637-6DFA-43B0-881B-364E49C30508Q36153123-67A10601-E205-4525-80DF-7A7F4003D59BQ36389868-06A56041-6794-42FC-BF62-DAEEDE75109CQ36443421-65B14E6B-B258-4D76-8E51-66661D908240Q36660677-18D71CAF-9756-445A-B0DE-C3B69C2419FFQ36850900-2F31775F-631A-445A-BFB0-53512EB6733BQ36939668-CD905404-DF00-4B23-9F8C-E10D5B92D6DEQ36949546-95D8ABBB-C98A-4A56-B214-5670905B3587Q37068767-C8CDB22A-E238-4176-9B78-424682683E5AQ37080936-7EBA77C6-589A-4B74-81A4-66D6B72ECC93
P2860
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@ast
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@en
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@nl
type
label
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@ast
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@en
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@nl
prefLabel
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@ast
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@en
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Phase I/II study of the Src in ...... ed non-small-cell lung cancer.
@en
P2093
Alberto Chiappori
Anthony Neuger
Bhupendra Rawal
Charles Williams
Eric B Haura
George Simon
Gerold Bepler
Jhanelle Gray
Lanxi Song
Leticia Tetteh
P2860
P304
P356
10.1200/JCO.2009.25.4029
P407
P577
2010-02-08T00:00:00Z